Physician profile
Sharon Sadr
NPI 1801916531
$887.65
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $374 · 2021: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.31 | 2019-2020 | |
| Amarin Pharma, INC. | $111.20 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $92.26 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $81.45 | 2019 | |
| Allergan, INC. | $79.57 | 2020 | |
| Pfizer INC. | $60.77 | 2020-2021 | |
| Almatica Pharma LLC | $51.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $45.53 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.68 | 2019 | |
| Amgen INC. | $37.03 | 2019 | |
| Nestle Healthcare Nutrition INC. | $32.14 | 2020-2021 | |
| Mylan Specialty L.P. | $30.44 | 2019-2021 | |
| Daiichi Sankyo INC. | $17.48 | 2021 | |
| Ucb, INC. | $17.43 | 2019 | |
| Lilly USA, LLC | $14.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $14.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Sadr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.